ATE239507T1 - Polymergebundene camptothecin-derivate - Google Patents

Polymergebundene camptothecin-derivate

Info

Publication number
ATE239507T1
ATE239507T1 AT94928387T AT94928387T ATE239507T1 AT E239507 T1 ATE239507 T1 AT E239507T1 AT 94928387 T AT94928387 T AT 94928387T AT 94928387 T AT94928387 T AT 94928387T AT E239507 T1 ATE239507 T1 AT E239507T1
Authority
AT
Austria
Prior art keywords
pct
formula
camptothecin
units represented
hydroxy
Prior art date
Application number
AT94928387T
Other languages
English (en)
Inventor
Francesco Angelucci
Antonino Suarato
Original Assignee
Pharmacia Italia Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Italia Spa filed Critical Pharmacia Italia Spa
Application granted granted Critical
Publication of ATE239507T1 publication Critical patent/ATE239507T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Saccharide Compounds (AREA)
  • Peptides Or Proteins (AREA)
AT94928387T 1993-10-08 1994-09-21 Polymergebundene camptothecin-derivate ATE239507T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB939320781A GB9320781D0 (en) 1993-10-08 1993-10-08 Polymer-bound camptothecin derivatives
PCT/EP1994/003154 WO1995010304A1 (en) 1993-10-08 1994-09-21 Polymer-bound camptothecin derivatives

Publications (1)

Publication Number Publication Date
ATE239507T1 true ATE239507T1 (de) 2003-05-15

Family

ID=10743226

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94928387T ATE239507T1 (de) 1993-10-08 1994-09-21 Polymergebundene camptothecin-derivate

Country Status (24)

Country Link
US (1) US5773522A (de)
EP (1) EP0673258B1 (de)
JP (1) JPH08504217A (de)
KR (1) KR100359005B1 (de)
CN (1) CN1138565C (de)
AT (1) ATE239507T1 (de)
AU (1) AU679788B2 (de)
CA (1) CA2150132A1 (de)
DE (1) DE69432627T2 (de)
DK (1) DK0673258T3 (de)
ES (1) ES2198421T3 (de)
FI (1) FI952746A0 (de)
GB (1) GB9320781D0 (de)
HU (1) HU215588B (de)
IL (1) IL111173A (de)
MY (1) MY116624A (de)
NZ (1) NZ273952A (de)
PL (1) PL178132B1 (de)
PT (1) PT673258E (de)
RU (1) RU2149646C1 (de)
TW (1) TW316905B (de)
UA (1) UA42706C2 (de)
WO (1) WO1995010304A1 (de)
ZA (1) ZA947823B (de)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5880131A (en) * 1993-10-20 1999-03-09 Enzon, Inc. High molecular weight polymer-based prodrugs
US5965566A (en) * 1993-10-20 1999-10-12 Enzon, Inc. High molecular weight polymer-based prodrugs
US5646159A (en) * 1994-07-20 1997-07-08 Research Triangle Institute Water-soluble esters of camptothecin compounds
DE19512484A1 (de) 1995-04-04 1996-10-17 Bayer Ag Kohlenhydratmodifizierte Cytostatika
SG50747A1 (en) * 1995-08-02 1998-07-20 Tanabe Seiyaku Co Comptothecin derivatives
CA2192725C (en) * 1995-12-28 2004-04-20 Kenji Tsujihara Camptothecin derivatives
US6441025B2 (en) * 1996-03-12 2002-08-27 Pg-Txl Company, L.P. Water soluble paclitaxel derivatives
WO1998014459A1 (de) * 1996-09-30 1998-04-09 Bayer Aktiengesellschaft Glycokonjugate von modifizierten camptothecin-derivaten (20-o-verknüpfung)
DE19640969A1 (de) * 1996-10-04 1998-04-16 Bayer Ag 20-0-verknüpfte Glycokonjugate von Camptothecin
ID23424A (id) * 1997-05-14 2000-04-20 Bayer Ag Glikokonjugat dari 20(s)-kamptotesin
GB9721069D0 (en) * 1997-10-03 1997-12-03 Pharmacia & Upjohn Spa Polymeric derivatives of camptothecin
GB9721070D0 (en) * 1997-10-03 1997-12-03 Pharmacia & Upjohn Spa Bioactive derivatives of camptothecin
US6153655A (en) * 1998-04-17 2000-11-28 Enzon, Inc. Terminally-branched polymeric linkers and polymeric conjugates containing the same
GB9915180D0 (en) * 1999-06-29 1999-09-01 Pharmacia & Upjohn Spa Antitumour compound
EP2266607A3 (de) 1999-10-01 2011-04-20 Immunogen, Inc. Immunokonjugate für Krebsbehandlung
US20030054977A1 (en) * 1999-10-12 2003-03-20 Cell Therapeutics, Inc. Manufacture of polyglutamate-therapeutic agent conjugates
AU1820400A (en) * 1999-11-17 2001-05-30 School Of Pharmacy, University Of London, The Conjugates of hpma copolymer and ellipticin
US20020077290A1 (en) * 2000-03-17 2002-06-20 Rama Bhatt Polyglutamic acid-camptothecin conjugates and methods of preparation
GB0008928D0 (en) * 2000-04-11 2000-05-31 Pharmacia & Upjohn Spa A method of administering an antitumour compound
US6350756B1 (en) 2001-01-18 2002-02-26 California Pacific Medical Center Camptothecin derivatives
US6855720B2 (en) 2001-03-01 2005-02-15 California Pacific Medical Center Nitrogen-based camptothecin derivatives
US6403604B1 (en) 2001-03-01 2002-06-11 California Pacific Medical Center Nitrogen-based camptothecin derivatives
WO2003033525A1 (en) * 2001-10-12 2003-04-24 Debio Recherche Pharmacuetique S.A. Amino-substituted camptothecin polymer derivatives and use of the same for the manufacture of a medicament
AU2003243380A1 (en) 2002-06-03 2003-12-19 California Pacific Medical Center Nitrogen-based homo-camptothecin derivatives
US7875602B2 (en) 2005-10-21 2011-01-25 Sutter West Bay Hospitals Camptothecin derivatives as chemoradiosensitizing agents
CN101265331B (zh) * 2007-03-12 2010-10-13 中国科学院化学研究所 Peg改性phpma材料及其制备方法
WO2011150022A2 (en) 2010-05-25 2011-12-01 Syndevrx, Inc. Polymer-conjugated metap2 inhibitors, and therapeutic methods of use thereof
US9895449B2 (en) 2010-05-25 2018-02-20 Syndevrx, Inc. Polymer-conjugated MetAP2 inhibitors, and therapeutic methods of use thereof
DK2984085T3 (da) 2013-04-10 2019-10-21 Syndevrx Inc Modificerede eller polymerkonjugerede fumagillol metap2-hæmmere til anvendelse i behandling af fedme
WO2015029615A1 (ja) * 2013-08-26 2015-03-05 独立行政法人科学技術振興機構 接着剤
KR20180093995A (ko) 2015-12-10 2018-08-22 신데브알엑스, 인크. 푸마길롤 유도체 및 그의 다형체
US10646463B2 (en) 2016-01-11 2020-05-12 Syndevrx, Inc. Treatment for tumors driven by metabolic dysfunction
CN113453721A (zh) 2018-10-26 2021-09-28 辛德弗雷克斯公司 Metap2抑制剂的生物标志物及其应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4943579A (en) * 1987-10-06 1990-07-24 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Water soluble prodrugs of camptothecin
GB9200247D0 (en) * 1992-01-07 1992-02-26 Erba Carlo Spa Pharmaceutical compositions containing polymer derivative-bound anthracycline glycosides and a method for their preparation
US5258453A (en) * 1992-01-21 1993-11-02 University Of Utah Drug delivery system for the simultaneous delivery of drugs activatable by enzymes and light
GB9213077D0 (en) * 1992-06-19 1992-08-05 Erba Carlo Spa Polymerbound taxol derivatives
GB9309663D0 (en) * 1993-05-11 1993-06-23 Erba Carlo Spa Biologically active compounds

Also Published As

Publication number Publication date
IL111173A (en) 1998-10-30
HUT71678A (en) 1996-01-29
UA42706C2 (uk) 2001-11-15
GB9320781D0 (en) 1993-12-01
PL309328A1 (en) 1995-10-02
RU95112841A (ru) 1997-06-27
EP0673258A1 (de) 1995-09-27
CN1115564A (zh) 1996-01-24
FI952746A (fi) 1995-06-05
WO1995010304A1 (en) 1995-04-20
DE69432627D1 (en) 2003-06-12
MY116624A (en) 2004-03-31
CA2150132A1 (en) 1995-04-20
RU2149646C1 (ru) 2000-05-27
HU9502084D0 (en) 1995-09-28
AU679788B2 (en) 1997-07-10
ZA947823B (en) 1995-07-03
FI952746A0 (fi) 1995-06-05
US5773522A (en) 1998-06-30
ES2198421T3 (es) 2004-02-01
NZ273952A (en) 1996-10-28
DK0673258T3 (da) 2003-08-25
HU215588B (hu) 1999-01-28
PT673258E (pt) 2003-09-30
JPH08504217A (ja) 1996-05-07
PL178132B1 (pl) 2000-03-31
AU7783694A (en) 1995-05-04
KR100359005B1 (ko) 2003-04-26
DE69432627T2 (de) 2004-03-25
TW316905B (de) 1997-10-01
EP0673258B1 (de) 2003-05-07
CN1138565C (zh) 2004-02-18
IL111173A0 (en) 1994-12-29

Similar Documents

Publication Publication Date Title
ATE239507T1 (de) Polymergebundene camptothecin-derivate
MX9408969A (es) Composisciones farmaceuticas que comprenden microparticulas biodegradables y biocompatibles para el tratamiento de transtornos psicoticos, su uso y procedimiento para prepararlas.
TW283716B (de)
EP0694558A4 (de) Sphingoglycolipid und verwendung davon
DK0819132T3 (da) Fremgangsmåde til fremstilling af anthracyclin-antibiotika
CA2028094A1 (en) Carbohydrateacryl- and methacrylcopolymers and their manufacture
IL125926A0 (en) Compounds related to the amidinium family pharmaceutical compositions containing them and uses thereof
AU6257394A (en) New derivatives of glutamic and aspartic acids, a method of preparing them, and their use as drugs for enhancing memory and learning
TW268015B (de)
BR9508384A (pt) Derivados de piridoÚ3,2,2-i,j¾ Ú3,1¾benzaxozina
HUP9802072A2 (hu) Benzo-tiopiráno-indazol-származékok és az ezeket tartalmazó gyógyszerkészítmények
IL115585A (en) Dipeptide derivatives processes for the preparation thereof and pharmaceutical compositions containing them
MY131175A (en) Heterocyclic compounds
CA2201096A1 (en) Solid dispersion and solid dispersion dosage form of xanthine derivative

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0673258

Country of ref document: EP

REN Ceased due to non-payment of the annual fee